Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials - PubMed
5 hours ago
- #meta-analysis
- #gynecologic-cancer
- #metformin
- Metformin combined with standard therapy did not significantly improve progression-free survival (PFS) or overall survival (OS) in gynecologic malignancies based on five randomized controlled trials involving 705 patients.
- Subgroup analyses showed no survival benefits for cervical or endometrial cancer, while a single ovarian cancer study suggested possible PFS improvement but with limited reliability due to a wide confidence interval.
- The meta-analysis concludes that current evidence does not support metformin's significant efficacy, and further large-scale, long-term trials are needed to explore potential benefits in specific patient subgroups or with novel therapies.